Atypical femur fractures: 81 individual personal histories

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 12, 2012, Pages 4324-4328

  Schneider, Jennifer P ^a   Hinshaw, William B ^b   Su, Christina ^c   Solow, Phyllis ^d  

^a Arizona Community Physicians   (United States)

^b Harris Regional Hospital   (United States)

^c IBM   (United States)

^d PORTLAND COMMUNITY COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; ATYPICAL FEMUR FRACTURE; FEMALE; FEMUR FRACTURE; FOOT FRACTURE; FRACTURE NONUNION; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METATARSUS FRACTURE; OSTEOPENIA; OSTEOPOROSIS; PAIN; PRIORITY JOURNAL; STRESS FRACTURE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; OSTEOPOROSIS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84870726486     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2590     Document Type: Article

References (18)

1. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620 (Pubitemid 30174014)
2. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301 (Pubitemid 40463979)
3. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M 2010 Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294
4. 2011 Transcript for the September 9, 2011 joint meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Available for free access at http://www.fda.gov/ as UCM275810.pdf
5. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A 2011 Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783-789
6. Schneider JP 2006 Should bisphosphonates be continued indefinitely? Geriatrics 61:31-33
7. Lane JM 2011 Evidence-based orthopedics: commentary. J Bone Joint Surg 93:1546
8. Dell R, Greene D, Ott S, Silverman S, Isemon E, Funahashi T, Adams A 2010 A retrospective analysis of atypical femur fractures in a large California HMO from the years 2007 to 2009. Proc 32nd Annual Meeting of the American Society for Bone and Mineral Research, Toronto, Canada, 2010 (Oral Presentation no. 1201, Abstract)
9. Meier RP, Perneger TV, Stern R, Rizzoli R, Peter RE 2012 Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 172:930-936
10. FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. Oct 13, 2010. Accessible free at http://www.fda.gov/Drugs/DrugSafety/ucm229009.htm
11. Giusti A, Hamdy NA, Papapoulos SE 2010 Atypical fractures of the femur and bisphosphonate use. A systematic review of case/case series studies. Bone 47:169-180
12. Berger FH, de Jonge MC, Maas M 2007 Stress fractures in the lower extremity: the importance of increasing awareness amongst radiologists. Eur J Radiol 62:16-26 (Pubitemid 46413634)
13. Das De S, Setiobudi T, Shen L, Das De S 2010 A rational approach to management of alendronate- related subtrochanteric fractures. J Bone Joint Surg Br 92:679-686
14. Dell R, Greene D, Tran D, Stopping bisphosphonate treatment decreases the risk of having a second atypical femur fracture. Proc 79th Annual Meeting of the American Academy of Orthopedic Surgeons, San Francisco, CA, 2012 (Abstract 190)
15. Edwards MH, McCrae FC, Young-Min SA 2010 Alendronate-related femoral diaphysis fracture-what should be done to predict and prevent subsequent fracture of the contralateral side? Osteoporos Int 21:701-703
16. Ward W, Carter CJ 2012 Bisphosphonate-associated subtrochanteric stress fractures: an emerging epidemic. J Bone Joint Surg Br 94(Suppl XXV): 256 (Abstract)
17. Viera RL, Rosenberg ZS, Peck V, Allison M, Im S, Are screening radiographs necessary to detect incomplete atypical femoral fractures in asymptomatic patients on long-term bisphosphonate therapy? Proc 97th Scientific Assembly and Annual Meeting of Radiological Society of North America, Chicago, 2011 (Abstract SSG09-05)
18. Imbuldeniya AM, Jiwa N, Murphy JP 2012 Bilateral atypical insufficiency fractures of the proximal tibia and a unilateral distal femoral fracture associated with long-term intravenous bisphosphonate therapy: a case report. J Med Case Rep 6:50